These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24528138)

  • 1. Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients.
    Vezina HE; Brundage RC; Balfour HH
    Br J Clin Pharmacol; 2014 Aug; 78(2):343-52. PubMed ID: 24528138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
    Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
    Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.
    Perrottet N; Decosterd LA; Meylan P; Pascual M; Biollaz J; Buclin T
    Clin Pharmacokinet; 2009; 48(6):399-418. PubMed ID: 19650679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.
    Pescovitz MD; Ettenger RB; Strife CF; Sherbotie JR; Thomas SE; McDiarmid S; Bartosh S; Ives J; Bouw MR; Bucuvalas J
    Transpl Infect Dis; 2010 Jun; 12(3):195-203. PubMed ID: 20002356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients.
    Zhao W; Baudouin V; Zhang D; Deschênes G; Le Guellec C; Jacqz-Aigrain E
    Clin Pharmacokinet; 2009; 48(5):321-8. PubMed ID: 19566115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.
    Wiltshire H; Hirankarn S; Farrell C; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N;
    Clin Pharmacokinet; 2005; 44(5):495-507. PubMed ID: 15871635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.
    Caldés A; Colom H; Armendariz Y; Garrido MJ; Troconiz IF; Gil-Vernet S; Lloberas N; Pou L; Peraire C; Grinyó JM
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4816-24. PubMed ID: 19738014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir.
    Perrottet N; Csajka C; Pascual M; Manuel O; Lamoth F; Meylan P; Aubert JD; Venetz JP; Soccal P; Decosterd LA; Biollaz J; Buclin T
    Antimicrob Agents Chemother; 2009 Jul; 53(7):3017-23. PubMed ID: 19307355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients.
    Wiltshire H; Paya CV; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Zuideveld KP;
    Transplantation; 2005 Jun; 79(11):1477-83. PubMed ID: 15940035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
    Perrottet N; Manuel O; Lamoth F; Venetz JP; Sahli R; Decosterd LA; Buclin T; Pascual M; Meylan P
    BMC Infect Dis; 2010 Jan; 10():2. PubMed ID: 20053269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of valganciclovir pharmacokinetics in lung transplant recipients.
    Kiser TH; Fish DN; Zamora MR
    J Heart Lung Transplant; 2012 Feb; 31(2):159-66. PubMed ID: 22305377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days.
    Welker H; Farhan M; Humar A; Washington C
    Transplantation; 2010 Dec; 90(12):1414-9. PubMed ID: 21076372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
    Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F
    Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of ganciclovir and valganciclovir in the adult horse.
    Carmichael RJ; Whitfield C; Maxwell LK
    J Vet Pharmacol Ther; 2013 Oct; 36(5):441-9. PubMed ID: 23301502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients.
    Franck B; Woillard JB; Théorêt Y; Bittencourt H; Demers E; Briand A; Marquet P; Lapeyraque AL; Ovetchkine P; Autmizguine J
    Br J Clin Pharmacol; 2021 Aug; 87(8):3105-3114. PubMed ID: 33373493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation.
    Acosta EP; Brundage RC; King JR; Sánchez PJ; Sood S; Agrawal V; Homans J; Jacobs RF; Lang D; Romero JR; Griffin J; Cloud G; Whitley R; Kimberlin DW;
    Clin Pharmacol Ther; 2007 Jun; 81(6):867-72. PubMed ID: 17392728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract.
    Winston DJ; Baden LR; Gabriel DA; Emmanouilides C; Shaw LM; Lange WR; Ratanatharathorn V
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):635-40. PubMed ID: 16737936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualization of valganciclovir prophylaxis for cytomegalovirus infection in pediatric kidney transplant patients.
    Zhao W; Fakhoury M; Fila M; Baudouin V; Deschênes G; Jacqz-Aigrain E
    Ther Drug Monit; 2012 Jun; 34(3):326-30. PubMed ID: 22495424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens.
    Tängdén T; Cojutti PG; Roberts JA; Pea F
    Clin Pharmacokinet; 2018 Nov; 57(11):1399-1405. PubMed ID: 29546589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients.
    Perrottet N; Robatel C; Meylan P; Pascual M; Venetz JP; Aubert JD; Berger MM; Decosterd LA; Buclin T
    J Antimicrob Chemother; 2008 Jun; 61(6):1332-5. PubMed ID: 18344549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.